Mineralys Therapeutics, Inc.
MLYS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $885,556 | $844,228 | $614,971 |
| - Cash | $217,597 | $101,788 | $165,007 | $114,091 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $783,768 | $679,221 | $500,880 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$15 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$36,917 | -$46,730 | -$44,432 | -$51,752 |
| % Margin | – | – | – | – |
| Net Income | -$36,932 | -$43,274 | -$42,211 | -$48,946 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.52 | -0.66 | -0.79 | -0.98 |
| % Growth | 21.2% | 16.5% | 19.4% | – |
| Operating Cash Flow | -$28,872 | -$30,169 | -$45,487 | -$66,843 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$28,872 | -$30,169 | -$45,487 | -$66,843 |